Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTUNASDAQ:BCAXNASDAQ:EOLSNASDAQ:ETNB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$6.69+9.1%$9.04$5.50▼$11.99$131.16MN/A58,196 shs99,538 shsBCAXBicara Therapeutics$9.29-1.8%$11.91$7.80▼$28.09$506.40MN/A675,943 shs202,378 shsEOLSEvolus$9.26+0.7%$10.11$8.67▼$17.82$597.41M0.97750,188 shs451,414 shsETNB89BIO$10.07+3.4%$9.06$4.16▼$11.84$1.47B1.281.51 million shs1.17 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics+0.33%-9.19%-46.04%-11.29%+612,999,900.00%BCAXBicara Therapeutics+1.83%-0.53%+1.94%-28.66%+945,999,900.00%EOLSEvolus-0.11%-4.37%-1.81%-24.71%-16.97%ETNB89BIO-0.92%-0.82%-2.21%+35.33%+25.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACTUActuate Therapeutics2.8928 of 5 stars3.50.00.00.03.63.30.0BCAXBicara TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AEOLSEvolus4.0693 of 5 stars3.50.00.03.53.33.30.6ETNB89BIO1.9397 of 5 stars3.51.00.00.02.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 3.00Buy$20.50206.66% UpsideBCAXBicara Therapeutics 3.00Buy$31.86243.12% UpsideEOLSEvolus 3.00Buy$23.75156.48% UpsideETNB89BIO 3.00Buy$26.43162.58% UpsideCurrent Analyst Ratings BreakdownLatest ACTU, ETNB, EOLS, and BCAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/11/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/3/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$20.005/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/23/2025BCAXBicara TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$8.005/23/2025BCAXBicara TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$30.005/16/2025BCAXBicara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $41.005/10/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/8/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/30/2025ETNB89BIOCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/A$0.01 per shareN/ABCAXBicara TherapeuticsN/AN/AN/AN/A$9.04 per shareN/AEOLSEvolus$266.27M2.24N/AN/A$0.09 per share102.89ETNB89BION/AN/AN/AN/A$3.34 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$27.28MN/A0.00∞N/AN/AN/A-339.73%N/ABCAXBicara Therapeutics-$68MN/A0.00N/AN/AN/AN/AN/A8/12/2025 (Estimated)EOLSEvolus-$50.42M-$0.89N/AN/AN/A-20.40%-759.04%-20.14%7/30/2025 (Estimated)ETNB89BIO-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)Latest ACTU, ETNB, EOLS, and BCAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025EOLSEvolus-$0.09N/AN/AN/A$82.18 millionN/A5/15/2025Q1 2025ACTUActuate Therapeutics-$0.26-$0.32-$0.06-$0.32N/AN/A5/13/2025Q1 2025BCAXBicara Therapeutics-$0.40-$0.68-$0.28-$0.68N/AN/A5/1/2025Q1 2025ETNB89BIO-$0.50-$0.49+$0.01-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/ABCAXBicara TherapeuticsN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A0.460.46BCAXBicara TherapeuticsN/A24.6224.62EOLSEvolus22.002.342.16ETNB89BIO0.0618.0318.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/ABCAXBicara TherapeuticsN/AEOLSEvolus90.69%ETNB89BION/AInsider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics69.34%BCAXBicara TherapeuticsN/AEOLSEvolus6.10%ETNB89BIO2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1019.62 million6.02 millionN/ABCAXBicara Therapeutics3254.54 millionN/AN/AEOLSEvolus17064.48 million60.54 millionOptionableETNB89BIO40145.98 million141.90 millionOptionableACTU, ETNB, EOLS, and BCAX HeadlinesRecent News About These Companies89BIO (NASDAQ:ETNB) Receives $26.43 Consensus PT from BrokeragesJune 30 at 3:43 AM | americanbankingnews.com89BIO (NASDAQ:ETNB) Given "Sell (D-)" Rating at Weiss RatingsJune 28, 2025 | americanbankingnews.com89BIO's (ETNB) "Sell (D-)" Rating Reaffirmed at Weiss RatingsJune 28, 2025 | marketbeat.com89BIO (NASDAQ:ETNB) Given Average Recommendation of "Buy" by AnalystsJune 25, 2025 | marketbeat.comAssenagon Asset Management S.A. Increases Holdings in 89bio, Inc. (NASDAQ:ETNB)June 16, 2025 | marketbeat.com89bio (NASDAQ:ETNB) Trading Up 4.9% - What's Next?June 13, 2025 | marketbeat.com89bio (NASDAQ:ETNB) Shares Down 4.8% - Here's What HappenedJune 12, 2025 | marketbeat.comHarbor Capital Advisors Inc. Buys 62,874 Shares of 89bio, Inc. (NASDAQ:ETNB)June 12, 2025 | marketbeat.com89bio (NASDAQ:ETNB) Receives Sell (D-) Rating from Weiss RatingsJune 12, 2025 | marketbeat.comBrokers Offer Predictions for 89bio FY2026 EarningsJune 11, 2025 | marketbeat.com89bio, Inc. (NASDAQ:ETNB) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCJune 9, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Raises Position in 89bio, Inc. (NASDAQ:ETNB)June 7, 2025 | marketbeat.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 6, 2025 | globenewswire.com89bio to Participate in Goldman Sachs 46th Annual Global Healthcare ConferenceJune 4, 2025 | globenewswire.comTwo Sigma Investments LP Sells 131,167 Shares of 89bio, Inc. (NASDAQ:ETNB)June 3, 2025 | marketbeat.comTwo Sigma Advisers LP Reduces Holdings in 89bio, Inc. (NASDAQ:ETNB)June 2, 2025 | marketbeat.com89bio, Inc. (NASDAQ:ETNB) Shares Bought by Bank of America Corp DEJune 2, 2025 | marketbeat.com89bio (ETNB) Receives a Buy from Bank of America SecuritiesMay 29, 2025 | theglobeandmail.comIs Now the Time to Buy Biotech Stocks?May 13, 2025 | finance.yahoo.comWhy 89bio, Inc. (ETNB) Is Among the Best Low Priced Biotech Stocks to Buy NowMay 13, 2025 | insidermonkey.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeMicron Joins Latest $200 Billion United States Investment By Gabriel Osorio-Mazilli | June 16, 2025View Micron Joins Latest $200 Billion United States Investment Constellation Energy and Meta Strike Nuclear Deal, Shares WhipsawBy Leo Miller | June 4, 2025View Constellation Energy and Meta Strike Nuclear Deal, Shares WhipsawTesla Stock: Why These 2 Downgrades Are Actually a Buy SignalBy Sam Quirke | June 11, 2025View Tesla Stock: Why These 2 Downgrades Are Actually a Buy SignalACTU, ETNB, EOLS, and BCAX Company DescriptionsActuate Therapeutics NASDAQ:ACTU$6.68 +0.56 (+9.05%) As of 02:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Bicara Therapeutics NASDAQ:BCAX$9.28 -0.18 (-1.85%) As of 02:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Evolus NASDAQ:EOLS$9.26 +0.06 (+0.65%) As of 02:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.89BIO NASDAQ:ETNB$10.06 +0.34 (+3.44%) As of 02:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Why Realty Income’s 5.59% Yield Makes It a Must-Buy REIT Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
